Literature DB >> 32250034

Nanoparticle-Based Platform for Activatable Fluorescence Imaging and Photothermal Ablation of Endometriosis.

Abraham S Moses1, Olena R Taratula1, Hyelim Lee1, Fangzhou Luo2, Tanner Grenz2, Tetiana Korzun1, Anna St Lorenz1, Fahad Y Sabei1, Shay Bracha3, Adam W G Alani1, Ov D Slayden2, Oleh Taratula1.   

Abstract

Endometriosis is a painful disorder where endometrium-like tissue forms lesions outside of the uterine cavity. Intraoperative identification and removal of these lesions are difficult. This study presents a nanoplatform that concurrently delineates and ablates endometriosis tissues using real-time near-infrared (NIR) fluorescence and photothermal therapy (PTT). The nanoplatform consists of a dye, silicon naphthalocyanine (SiNc), capable of both NIR fluorescence imaging and PTT, and a polymeric nanoparticle as a SiNc carrier to endometriosis tissue following systemic administration. To achieve high contrast during fluorescence imaging of endometriotic lesions, nanoparticles are constructed to be non-fluorescent prior to internalization by endometriosis cells. In vitro studies confirm that these nanoparticles activate the fluorescence signal following internalization in macaque endometrial stromal cells and ablate them by increasing cellular temperature to 53 ° C upon interaction with NIR light. To demonstrate in vivo efficiency of the nanoparticles, biopsies of endometrium and endometriosis from rhesus macaques are transplanted into immunodeficient mice. Imaging with the intraoperative Fluobeam 800 system reveals that 24 h following intravenous injection, nanoparticles efficiently accumulate in, and demarcate, endometriotic grafts with fluorescence. Finally, the nanoparticles increase the temperature of endometriotic grafts up to 47 °C upon exposure to NIR light, completely eradicating them after a single treatment.
© 2020 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim.

Entities:  

Keywords:  endometriosis; fluorescence imaging; nanoparticles; photothermal therapy

Year:  2020        PMID: 32250034      PMCID: PMC7210057          DOI: 10.1002/smll.201906936

Source DB:  PubMed          Journal:  Small        ISSN: 1613-6810            Impact factor:   13.281


  46 in total

Review 1.  Recurrence of endometriosis and its control.

Authors:  Sun-Wei Guo
Journal:  Hum Reprod Update       Date:  2009-03-11       Impact factor: 15.610

2.  Near infrared fluorescence for image-guided surgery.

Authors:  Summer L Gibbs
Journal:  Quant Imaging Med Surg       Date:  2012-09

3.  Recurrence rate of endometriomas following a laparoscopic cystectomy.

Authors:  Iwaho Kikuchi; Hiroyuki Takeuchi; Mari Kitade; Hiroto Shimanuki; Jun Kumakiri; Katsuyuki Kinoshita
Journal:  Acta Obstet Gynecol Scand       Date:  2006       Impact factor: 3.636

4.  Molecular evidence for differences in endometrium in severe versus mild endometriosis.

Authors:  Lusine Aghajanova; Linda C Giudice
Journal:  Reprod Sci       Date:  2010-11-09       Impact factor: 3.060

Review 5.  Endometriosis: pathogenesis and treatment.

Authors:  Paolo Vercellini; Paola Viganò; Edgardo Somigliana; Luigi Fedele
Journal:  Nat Rev Endocrinol       Date:  2013-12-24       Impact factor: 43.330

Review 6.  Endometriosis and infertility: epidemiology and evidence-based treatments.

Authors:  Sebiha Ozkan; William Murk; Aydin Arici
Journal:  Ann N Y Acad Sci       Date:  2008-04       Impact factor: 5.691

7.  Investigating the impact of nanoparticle size on active and passive tumor targeting efficiency.

Authors:  Edward A Sykes; Juan Chen; Gang Zheng; Warren C W Chan
Journal:  ACS Nano       Date:  2014-05-22       Impact factor: 15.881

8.  Temperature-tunable iron oxide nanoparticles for remote-controlled drug release.

Authors:  Raj K Dani; Canan Schumann; Olena Taratula; Oleh Taratula
Journal:  AAPS PharmSciTech       Date:  2014-05-13       Impact factor: 3.246

9.  Angiogenesis and endometriosis.

Authors:  Ana Luiza L Rocha; Fernando M Reis; Robert N Taylor
Journal:  Obstet Gynecol Int       Date:  2013-05-26

10.  Doxorubicin-Loaded PEG-PCL-PEG Micelle Using Xenograft Model of Nude Mice: Effect of Multiple Administration of Micelle on the Suppression of Human Breast Cancer.

Authors:  Nguyen-Van Cuong; Jian-Lin Jiang; Yu-Lun Li; Jim-Ray Chen; Shyh-Chuan Jwo; Ming-Fa Hsieh
Journal:  Cancers (Basel)       Date:  2010-12-28       Impact factor: 6.639

View more
  6 in total

Review 1.  Nanomedicines for Endometriosis: Lessons Learned from Cancer Research.

Authors:  Abraham S Moses; Ananiya A Demessie; Olena Taratula; Tetiana Korzun; Ov D Slayden; Oleh Taratula
Journal:  Small       Date:  2021-01-25       Impact factor: 13.281

2.  A Mouse Model of Endometriosis with Nanoparticle Labeling for In Vivo Photoacoustic Imaging.

Authors:  Ryan M Marquardt; Md Nafiujjaman; Tae Hoon Kim; Seock-Jin Chung; Kay Hadrick; Taeho Kim; Jae-Wook Jeong
Journal:  Reprod Sci       Date:  2022-05-31       Impact factor: 2.924

3.  Targeted Nanoparticles with High Heating Efficiency for the Treatment of Endometriosis with Systemically Delivered Magnetic Hyperthermia.

Authors:  Youngrong Park; Ananiya A Demessie; Addie Luo; Olena R Taratula; Abraham S Moses; Peter Do; Leonardo Campos; Younes Jahangiri; Cory R Wyatt; Hassan A Albarqi; Khashayar Farsad; Ov D Slayden; Oleh Taratula
Journal:  Small       Date:  2022-04-17       Impact factor: 15.153

4.  Animal Models of Adenomyosis.

Authors:  Ryan M Marquardt; Jae-Wook Jeong; Asgerally T Fazleabas
Journal:  Semin Reprod Med       Date:  2020-10-26       Impact factor: 1.303

5.  Discovery and Validation of a Compound to Target Ewing's Sarcoma.

Authors:  Ellie Esfandiari Nazzaro; Fahad Y Sabei; Walter K Vogel; Mohamad Nazari; Katelyn S Nicholson; Philip R Gafken; Olena Taratula; Oleh Taratula; Monika A Davare; Mark Leid
Journal:  Pharmaceutics       Date:  2021-09-24       Impact factor: 6.525

6.  Homing Peptide-Based Targeting of Tenascin-C and Fibronectin in Endometriosis.

Authors:  Lorena Simón-Gracia; Kristina Kiisholts; Vilma Petrikaitė; Allan Tobi; Merli Saare; Prakash Lingasamy; Maire Peters; Andres Salumets; Tambet Teesalu
Journal:  Nanomaterials (Basel)       Date:  2021-11-30       Impact factor: 5.076

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.